Merozyne Therapeutics has been established to develop a treatment for MDC1A, a severe form of muscular dystrophy.
Merozyne – muscular dystrophy
MDC1A is a rare and severe form of muscular dystrophy caused by mutations in the gene encoding the alpha2 chain of the extracellular matrix protein laminin (merosin). There is currently no cure for MDC1A. Patients have a degraded quality of life and often die before reaching adolescence. Although progress is being made to develop treatments for other forms of muscular dystrophy, most notably for Duchenne Muscular Dystrophy, little or no progress has been made in addressing the unmet medical needs of MDC1A patients. The drug development program now embarked on by Merozyne Therapeutics has the potential to offer new and unique possibilities to treat MDC1A. Such a new pharmaceutical treatment will provide improved quality of life and potentially a prolonged life span for the patient.
Merozyne is a biopharma company headquartered in Lund (Sweden). Management Team is composed by Madeleine Durbeej-Hjalt, Tomas Eriksson, Johan Evenäs, Eskil Söderlind and Björn Walse. Merozyne Therapeutics has recently announced that it has started a project aiming to develop a pharmaceutical treatment against laminin alpha2 chain-deficient congenital muscular dystrophy (MDC1A) by exploiting the unique research conducted by Prof. Madeleine Durbeej-Hjalt and Dr. Virginie Carmignac at Lund University. Merozyne Therapeutics will now raise a first round of capital to further advance the project and develop a clinical candidate.
More about Merozyne : http://merozyne.com